Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: * age ≥ 18 and ≤ 80 years old * estimated CLCR (eCLCR) ≥ 60 mL/min via Cockcroft-Gault equation Exclusion Criteria: * KDIGO classification ≥ 1 at day of screening * known HIV or HBV infection
About the study
Cefiderocol is a powerful, broad spectrum antibiotic approved to treat hospital-acquired or ventilator associated pneumonia and urinary tract infections. Although cefiderocol has labeled dosing recommendations, including augmented renal clearance, patients with burn injury remain an unstudied population at high risk for MDR pathogens. The primary objective of this study is to evaluate the pharmacokinetic principles of cefiderocol in patients after acute burn injury. Findings from this study will determine the dose and interval necessary to maintain therapeutic concentrations of cefiderocol in patients after burn injury for adequate bactericidal activity, prevention of resistance, and treatment outcomes.
What is being tested
- Cefiderocol (drug)
Sponsor: University of Tennessee · Participants: 12 · Started: Feb 16, 2026
Contact the study team
Official record on ClinicalTrials.gov — NCT07465432
Locations in the U.S.
| Tennessee | Regional One Health, Memphis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.